Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 2Phase 3 1

Status

Completed 5Terminated 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Recurrence 1Neoplasm Metastasis 1Colorectal Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Interferon-alpha × Clear all
NCT01545141 2023-10-27

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Roswell Park Cancer Institute

Phase 1/2 Terminated
15 enrolled 9 charts
Gastrointestinal

Neoplasm Metastasis, Recurrence, Colorectal Neoplasms

NCT00095862 2018-02-05

Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

National Cancer Institute (NCI)

Phase 1/2 Terminated
24 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡